Search results
Results From The WOW.Com Content Network
According to The New York Times, the label lists mild side effects like urinary tract and skin infections, but now that might have to be expanded to more serious health risks.. Related: First FDA ...
Tibial tuberosity advancement (TTA) is an orthopedic procedure to repair deficient cranial cruciate ligaments in dogs. It has also been used in cats. This procedure was developed by Dr. Slobodan Tepic and Professor Pierre Montavon at the School of Veterinary Medicine, University of Zurich, in Zurich, Switzerland beginning in the late 1990s.
In a TPLO procedure, the tibial plateau, the portion of the tibia adjoining the stifle, is cut and rotated so that its slope changes to approximately 5 degrees from the horizontal plane. [4] This prevents the femur from sliding down the slope of the tibial plateau when the dog puts weight on its knee. This surgery generally results in faster ...
The VIGOR trial results were published in 2000 in the New England Journal of Medicine [47] Bombardier and her research team claimed that there was "an increase in myocardial infarction in the patients given rofecoxib (0.4%) compared with those given naproxen (0.1%)" and "patients given naproxen experienced 121 side effects compared with 56 in ...
Celecoxib, sold under the brand name Celebrex among others, is a COX-2 inhibitor and nonsteroidal anti-inflammatory drug (NSAID). [7] It is used to treat the pain and inflammation in osteoarthritis, acute pain in adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, and juvenile rheumatoid arthritis. [7]
The dog medication Librela is likely sickening and killing dogs, the FDA warned. Ermolaev Alexandr – stock.adobe.com More than 3,600 cases of Librela harming dogs have been reported to the FDA.
Deracoxib is a coxib class nonsteroidal anti-inflammatory drug (NSAID). [3] Like other NSAIDs, its effects are caused by inhibition of cyclooxygenase (COX) enzymes. [7] At the doses used to treat dogs, deracoxib causes greater inhibition of COX-2 than of COX-1, [3] but at doses twice those recommended for use in dogs, deracoxib significantly inhibits COX-1 as well.
Type A: augmented pharmacological effects, which are dose-dependent and predictable [5]; Type A reactions, which constitute approximately 80% of adverse drug reactions, are usually a consequence of the drug's primary pharmacological effect (e.g., bleeding when using the anticoagulant warfarin) or a low therapeutic index of the drug (e.g., nausea from digoxin), and they are therefore predictable.